Frankfurt/Main – Össur, Nasdaq Copenhagen listed leading global provider of innovative mobility solutions, acquired all shares of privately owned Fior & Gentz, a Germany based leading European manufacturer of lower limb neuro orthotic components. Fior & Gentz develops and distributes knee and ankle orthotic joints to create innovative custom-made orthotic solutions for patients with gait impairments due to neurological conditions. The acquisition of Fior & Gentz represents an attractive opportunity for Össur to enter the fast-growing neuro orthotics market.
The transaction volume amounts to around EUR 100 million plus an earn-out of up to EUR 20 million. The payment consists of cash as well as of newly issued, listed shares of Icelandic Össur hf. to the sellers of Fior & Gentz.
An international CMS team led by Dr Heike Wagner and Dr Tobias Kilian advised Össur comprehensively on all legal aspects also in connection with this transaction.
CMS Germany
Dr Heike Wagner, Partner
Dr Tobias Kilian, Of Counsel, both Lead
Dr Reiner Thieme, Associate
Nathalie Amrhen, Associate, all Corporate / M&A
Jörg Schrade, Partner
Eduard Kosavtsev, Senior Associate, both Tax
Dr Roland Wiring, Partner
Dr Siham Hidar, Senior Associate
Noah Rodenkirchen, Associate, all Regulatory & Lifesciences
Dr Stefan Lehr, Partner, Antitrust, Competition & Trade
Dr Dirk Smielick, Principal Counsel, IP
Prof Dr Malte Grützmacher, Partner, IT
Dr Boris Alles, Partner
Dela Herr, Associate, both Labor, Employment & Pensions
Dr Franz Maurer, Counsel
Wiebke Westermann, Associate, both Real Estate & Public
CMS Netherlands
Roman Tarlavski, Partner
Marcellina Rietvelt, Associate, both Corporate / M&A
Martijn van der Bie, Partner
Gieneke van Nierop, Counsel, both Corporate / Notaries
CMS Norway
Nicolas Jorn Brunet, Partner
Tuva Svare, Associate, both Corporate / M&A
Henrik Nordling, Partner, Antitrust, Competition & Trade
Press Contact
presse@cms-hs.com
